How to access Cerezyme from Egypt — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Egyptian patient with Gaucher disease type 1 may receive a prescription for Cerezyme (imiglucerase) from their treating metabolic specialist, haematologist, or paediatrician as enzyme-replacement therapy. Cerezyme is FDA-approved in the United States for long-term treatment of Gaucher type 1. In Egypt, Cerezyme may not always be uniformly stocked in tertiary metabolic centres, which is why your specialist may be coordinating a named-patient import pathway on your behalf for ongoing infusion supply.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Cerezyme is an intravenous enzyme-replacement therapy (recombinant human glucocerebrosidase) administered as an infusion once every two weeks. Eligibility requires biochemical and/or genetic confirmation of Gaucher type 1. The manufacturer is Sanofi (Genzyme). Dosing is weight-based, typically 60 units/kg IV every two weeks, adjustable based on clinical response. The product requires refrigerated storage (2–8 degrees C) and reconstitution before infusion. Monitoring includes haematology, spleen/liver volumes, bone parameters, antibody development, and infusion-reaction surveillance. Your specialist will confirm diagnosis and coordinate the infusion plan.
Is Cerezyme legally importable into Egypt?
Yes — through the Egyptian Drug Authority (EDA) named-patient import framework, administered via the administering hospital's importing pharmacy and the EDA Central Administration of Pharmaceutical Affairs. Egypt has a mature named-patient mechanism that supports cross-border access to rare-disease therapies.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Because Cerezyme is cold-chain, chain-of-custody documentation includes continuous temperature logging.
How the pathway works, step by step
- Consultation with your treating specialist. The decision to prescribe Cerezyme is clinical, based on Gaucher type 1 confirmation and long-term management plan. Your specialist documents the rationale.
- Infusion-facility identification. An Egyptian tertiary hospital or infusion centre equipped for bi-weekly enzyme-replacement infusions accepts the case.
- EDA named-patient application. Your physician or the hospital's importing pharmacy files an application with EDA including clinical rationale, patient identifier, product details, and chain-of-custody plan with temperature logging.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Cerezyme travels with validated cold-chain packaging and continuous temperature logging end to end.
- Arrival and infusion. The infusion centre receives the product and administers under your specialist's care. Reserve Meds coordinates the next cycle ahead of depletion to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Gaucher type 1 diagnosis and Cerezyme as the indicated long-term therapy
- Verification of their Egyptian medical licence (MOH / Egyptian Medical Syndicate)
- A current prescription naming the product, dose (units/kg), and infusion schedule
- Patient identifier (anonymised reference preferred)
- The identified infusion facility and its cold-chain handling capability
Reserve Meds provides a physician documentation kit bundling the templates EDA reviewers expect to see for named-patient import of cold-chain enzyme-replacement therapies.
Costs and timing
Cerezyme's US cash-pay reference price is weight-dependent because dosing is weight-based. A typical adult annual cost sits in an indicative 2026 range of roughly USD 250,000–400,000 for ongoing bi-weekly infusions. Logistics, EDA documentation handling, cold-chain shipment, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete EDA application is submitted. Subsequent cycles are scheduled to match the bi-weekly infusion calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Cerezyme specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for EDA review.
- Logistics. Cold-chain shipment and chain-of-custody coordination with temperature logging.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating metabolic specialist and the infusion facility. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Egypt? Yes, when executed through the EDA named-patient framework with appropriate documentation. The pathway has been used routinely across rare disease for many years. See our trust and compliance page.
What if the cold chain breaks? Our protocol logs temperature continuously; any excursion is assessed against manufacturer stability data. If the product is compromised, we re-source at our cost per service terms.
Is Cerezyme the same as VPRIV? Both are enzyme-replacement therapies for Gaucher type 1 with similar efficacy profiles. Switching or choice between them is a clinical decision made by your specialist. We do not influence choice.
Will private insurance cover this? Cash-pay is the default. Some Egyptian private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Cerezyme coordination in Egypt.
Add me to the Cerezyme waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.